Development of transcatheter heart valve therapy in the world in 2020
- VernacularTitle:2020 年经导管瓣膜治疗主要进展
- Author:
Wenzhi PAN
1
;
Yuliang LONG
1
;
Daxin ZHOU
1
;
Junbo GE
1
Author Information
1. Department of Vasculocardiology, Zhongshan Hospital Fudan University, Shanghai, 200032, P.R.China
- Publication Type:Journal Article
- Keywords:
Transcatheter aortic valve therapy;
transcatheter aortic valve replacement;
interventional therapy;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(04):371-375
- CountryChina
- Language:Chinese
-
Abstract:
In 2020, due to the impact of the novel coronavirus epidemic, the development of transcatheter heart valve therapy has been shown to slow down, but there are still many aspects worth noting. The indication of monoclonal antibody after transcatheter aortic valve replacement (TAVR) should be further clarified. Low surgical risk patients were included in TAVR relative indications. Mitraclip G4 was approved by CE. The indication of atrial septal occlusion after mitraclip should be further clarified. The technique of coaptation augmentation is expected to become a new method of mitral valve interventional repair. Tendyne transcatheter mitral valve was approved by European Union. Transcatheter tricuspid valve treatment equipments, TriClip and PASCAL obtained CE mark. TAVR technology is being popularized rapidly in China, and what’s more, balloon dilated valve Sapien 3 and new recyclable repositioning valve system-Venus plus have entered the domestic market. A number of mitral valve therapeutic instruments have appeared one after another, and China's first tricuspid valve lux has completed its FIM research. Finally, with the improvement of devices and technology in the future, interventional therapy of heart valve is expected to benefit more patients.
